Address
1616 Eastlake Avenue East
Seattle, WA 98102
United States of America (the)
Phone
206 737 0085
Website
Sector
Healthcare
Industry
Biotechnology
Employees
60
First IPO Date
July 29, 2021
| Name | Title | Pay | Year Born |
| Adam K. Simpson | President, Chief Executive Officer, Co-Founder & Director | 855,950 | 1976 |
| Elizabeth Bekiroglu | General Counsel & Corporate Secretary | 230,737 | 1970 |
| Thomas Joseph Russo | Chief Financial Officer | 525,267 | 1972 |
| Cassia Cearley | Treasurer & Chief Business Officer | 632,150 | 1983 |
| Niranjan Kanesa-thasan | Chief Medical Officer | 641,550 | 1961 |
| Neil King | Chair of Scientific Advisory Board & Co-Founder | 0 | N/A |
| David Baker | Co-founder & Member of Scientific Advisory Board | 0 | N/A |
| Ami Shah Brown | Senior Vice President of Regulatory Affairs | 0 | N/A |
| Jennifer Raymond | Senior Vice President of Technical Operations | 0 | N/A |
| Lori Stewart | Senior Vice President of People & Culture | 0 | N/A |
Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing immunizations against infectious diseases. Leveraging its proprietary virus-like particle (VLP) platform technology, the company primarily focuses its efforts on severe respiratory illnesses. Its developmental portfolio includes several key vaccine candidates: IVX-121, an RSV-targeted vaccine currently undergoing Phase 1/1b clinical trials; IVX-A12, a bivalent candidate designed to target both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV); IVX-241, a candidate specifically designed for hMPV; and IVX-411, a SARS-CoV-2 vaccine based on a receptor binding domain (RBD) sequence antigen, which is also in Phase 1/2 clinical trials. Established in 2017, Icosavax maintains its corporate headquarters in Seattle, Washington.